XENOTRANSPLANT FOR CNS THERAPY

• US 20090047325A1
• Filed: 10/09/2008
• Published: 02/19/2009
• Est. Priority Date: 04/30/1999
• Status: Abandoned Application

• Current Assignee: Neurotrophincell Pty, Limited
• Original Assignee: Neurotrophincell Pty, Limited
• Inventors: Elliot, Robert Bartlett, Borlongan, Cesar Venturina, Williams, Christopher Edward, Vasconcellos, Alfred, Emerich, Dwaine, Skinner, Stephen John Martin
• Application Number:
  US12/248,490
• Publication Number:
  US 20090047325A1
• Time in Patent Office: Days
• US Class Current: 424/424
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61L 27/3813 Epithelial cells, e.g. keratinocytes, urothelial cells
• CPC Class Codes: A61L 27/3878 Nerve tissue, brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed are compositions and methods for the xenotransplantation treatment of neurological diseases of the central nervous system of a mammal.

Claims

1. An implant comprising living cells collected from the choroid plexus of a mammal, at least some of which cells are choroid epithelial cells, said implant being capable of secreting at least one product, having a beneficial effect on a neurological disease when transplanted into a recipient mammal suffering from said neurological disease.

2. The implant of claim 1, wherein the living cells are encapsulated within a biocompatible capsule, the wall of which is at least partially composed of a semipermeable membrane capable of admitting metabolites for sustaining the cells, capable of blocking access by factors of the immune system of the recipient mammal, and capable of allowing an effective amount of one or more expressed products to exit from the implant.

3. The implant of claim 2, wherein the biocompatible capsule has an inner layer including an effective amount of a laminin;

the laminin serving as a physical substrate for the living cells thereby providing orientation and support for the cells.

4. The implant of claim 3, wherein the biocompatible capsule comprises a globular containment means capable of holding living cells.

5. The implant of claim 3, wherein the biocompatible capsule comprises a tubular containment means capable of holding living cells;

the implant being capable of placement within a ventricle of the brain of the recipient mammal, so that the products expressed from the implant may access at least some regions of the central nervous system.

6. The implant of claim 1, wherein the living cells are taken from the choroid plexus of a fetal or neonatal mammal.

7. The implant of claim 1, wherein said living cells are obtained from the choroid plexus of a neonatal porcine.

8. The implant of claim 6, wherein at least some living cells have undergone subsequent modification in order to increase the production of at least one product capable of having a beneficial effect on a neurological disease.

9. A method of treating a neurological disorder in a mammal in need thereof comprising implanting in or near the brain of said mammal an implant of claim 1.

10. The method of claim 9, wherein said implant comprises living cells obtained from the choroid plexus of a neonatal porcine.

11. The method of claim 9, wherein the neurological disorder is selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, epilepsy, Huntington'"'"'s disease, stroke, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, aging, vascular disease, Menkes Kinky Hair Syndrome, Wilson'"'"'s disease, trauma or injury and damage to the nervous system.

12. The method of claim 11, wherein the neurological disorder is Huntington'"'"'s disease.

13. The method of claim 11, wherein the neurological disorder is a stroke.

14. The method of claim 11, wherein the neurological disorder is amyotrophic lateral sclerosis (ALS).

15. The method of claim 11, wherein the neurological disorder is Parkinson'"'"'s disease.

19. Isolated mammalian choroid plexus cells for use in the implant of claim 1.

20. Isolated mammalian neonatal choroid plexus cells for use in the implant of claim 1.

16. A use of live mammalian choroid plexus cells in the manufacture of an implant for treating or preventing a neurological disorder in a mammal.

17. The use of claim 16, wherein the neurological disorder is selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, epilepsy, Huntington'"'"'s disease, stroke, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, aging, vascular disease, Menkes Kinky Hair Syndrome, Wilson'"'"'s disease, trauma or injury and damage to the nervous system.

18. The use of claim 16, wherein said live cells are obtained from the choroid plexus of a neonatal porcine.